


Orientations for Work Programme 2012



Stéphane Hogan
Head of Unit – Horizontal Aspects
Health Directorate
DG Research & Innovation
European Commission

The 7th Framework programme (FP7)

- Introduction & Basic principles
- 2012 Work programme
 - Key features
 - Priorities
 - Conditions
 - Topics

Why ?

- to improve quality of life and
- to improve competitiveness of Europe
through collaboration

How ?

- by pooling resources (funds for Framework Programme)
- by coordinating national research programmes

Collaborative research in the Health theme

Main policy drivers:

- **Improving health** of European citizens
- **Increasing competitiveness** of European health-related industries and businesses
- **Addressing global health issues**, including emerging epidemics

Budget:

- **€6.1 billion over 7 years (2007-2013)**

Collaborative research across borders and other barriers

● between countries:

➔ At least 3 partners from the 27 EU Member States:

Austria, Belgium, Bulgaria, Czech Rep., Cyprus, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, the United Kingdom.

➔ or the 13 Associated Countries:

Albania, Bosnia-Herzegovina, Croatia, FYROM, Iceland, Israel, Liechtenstein, Montenegro, Norway, Serbia, Switzerland, Turkey and the Faroe Islands.

➔ In addition, researchers from anywhere in the world can participate:
e.g.: Australia, Brazil, Canada, China, Egypt, India, Japan, Korea, Russia, South-Africa, USA, ...
and in many cases, can be funded.

Drivers for FP7 from Innovation Union policy

- **Innovation-driven approach**
 - Focus on SMEs through genuine academia-industry collaborations
- **Challenge-driven approach**, focussed on key challenges
- **Support implementation of European Innovation Partnerships**, such as “Active and healthy ageing”
- **Stronger socio-economic impact** - innovation dimension
 - with more attention on **exploitation phase**
- **Balance** upstream research and activities closer to market in order to achieve short and medium-term impact

Features of FP7 Health in 2012 & 2013

- fewer, more prominent priorities
i.e. more focus on fewer areas
- fewer, broader topics, two-stage submission-evaluation
- greater emphasis on innovation
 - especially through SME-targeted topics
 - and continued support of clinical trials
- emphasis on flexibility for consortium, duration & budget
- international cooperation with more strategic focus

Main features:

- Indicative budget for 2012 calls: €650m (tbc)
- 2 “Health” calls:
 - FP7-HEALTH-2012-INNOVATION-1 (34 topics, €540m)
 - FP7-HEALTH-2012-INNOVATION-2 (3 topics, €108m)
 - FP7-2012-ERA-NET call (1 topic, €2m)
- Two-stage submission for ALL topics (except the ERA-NET)
- Several projects funded for MOST topics (29/38)
 - exceptions: 7 CSA, 1.4-3 (Australia) & 2.1.1-1-C (IP)
- 14 SME-targeted topics (including special call)
and 3 Industry-targeted topics (including SMEs)

Priorities of FP7 Health in 2012

Main priorities:

- **Ageing** will be the 1st priority in 2012 – budget ~€220m (incl. med. tech, biomarkers, clinical trials, co-morbidity, health services)
 - **Medical technologies** – €160m
 - **Rare diseases** – ~€100m
 - **SME targeted actions:**
 - 3 topics: $\geq 50\%$ EC contrib. to SMEs: €108m
 - 5 topics: $\geq 30\%$ EC contrib. to SMEs: €156m
 - 6 topics: $\geq 15\%$ EC contrib. to SMEs: €72m
- Total: 14 topics (out of 38 topics) – €336m (~50%)

NB: total budget: €650m (some overlap between priorities & budgets)

"SMEs for Innovation" INNOV-2 call

Aim: to stimulate innovation via enhanced SME participation

3 broad topics with a focus on medical technologies:

- 1.4-2 Medical technology for transplantation and bio-artificial organs
- 2.3.0-1 Diagnostics for infectious diseases (in humans)
- 2.4.5-1 Technological approaches to combating sensory impairment

Note: SME-targeted topics must include SMEs and these must have leading roles. However, these topics are also open to other entities.

"SMEs for Innovation" INNOV-2 call

Pilot initiative to stimulate innovation via enhanced SME participation

Special conditions:

- 3-5 partners, min. 50% of required EU funding for SME(s)
 - **Restricted to entities from EU and Associated Countries**
 - Maximum 3 years
 - The SME must have a leading role in the project
 - 2-stage submission & evaluation; **higher threshold for "Impact"**
 - Simplified application process: short project description
 - Accelerated procedures for submission, evaluation & negotiation i.e.: earlier deadlines for 1st and 2nd stage submission.
 - **First deadline: 27 September 2011*** (INNOV-1 call: 4 October)*
- [*: *to be confirmed in calls published on CORDIS in July 2011.*]

- Any research organisation can participate, including larger companies, as well as service-providers.
- However, the funding levels are different:
 - For academia & SMEs: 75% of research costs
 - (+ 100% management & training & eligible IP costs)
 - For larger companies: 50% of research costs
 - (+ 100% management & training & eligible IP costs)
- What is an SME ? (for the EC: 1 + 2 + 3)
 1. less than 250 employees
 2. annual turnover \leq €50 million OR balance sheet total \leq €43 million
 3. must be autonomous*

* check SME status: <http://ec.europa.eu/research/sme-techweb>

Aim:

- Translating research into clinical practice
- Different types of clinical trials,
e.g. investigator-driven, observational, ...

Scope:

- specified in each topic, phases covered are decided by the participants, and may be depend on the maximum possible allocated budget.
- expected to be mostly phase I, II, and IV - for details see specific topics and special instructions for clinical trials on page 9 of orientation paper.

Note:

- Importance of ethics issues
- Patient involvement
- Statistics

For any project, such as CTs, epidemiological studies or whenever applicable an appropriate study design, data processing and statistical analysis of results are important for the quality and efficiency of the science and reliability of conclusions, and hence also ethically.

This may for example include:

- description of experimental plan and data gathering,
- method for uncertainty or measurement error estimation,
- statistical analysis of data
- methods of inference (e.g. statistical tests and p-values to be used, accounting for multiple comparisons or small sample size, dealing with missing or noisy data)
- statistical power analysis and estimate (justification) of the number of needed animals or human subjects*.

*If these are not applicable or not justified, the proposal should briefly explain it.

Funding schemes for FP7 Health in 2012

Funding scheme	Ceiling for EU contribution	Number of topics	% budget
Large-scale integrating project (CP-IP)	€12m	4	~ 16.5%
Small or medium scale focused project (CP-FP)	€3m / €6m	24	~ 78%
Coordinating or supporting action (CSA)	various	10	~ 2.5%
Other actions*	various	–	~ 2%
Total		38	100%

* including HFSP0, EDCTP, study on emerging areas for research/innovation, study on impact of ethics review on health research, production of videos.

Single-stage call:

- 35/166 proposals short-listed
- Success rate: 21%
- €166.5m awarded

Two-stage call:

- 91/220 proposals short-listed
- Success rate: 41%
- €495.1m awarded

Overall

Average grant for research projects: >€5.5m

Clinical trials (8 topics):

- 26 projects; €152m awarded

SME-targeted topics (10):

- 34 projects; €221m awarded
- 15 projects led by SMEs

Basic principles for calls & evaluation

Peer review

Equality of treatment

Transparency

Aim: to fund the best R&D proposals

Submission & evaluation

Basic principles:

- Annual calls for proposals (in two stages)
- Evaluation by panels of independent experts overseen by Independent Observers
- 3 criteria:
 - ➔ Science & Technology excellence
 - ➔ Implementation & Management
 - ➔ Potential Impact
- Feedback: Evaluation Summary Reports (ESRs)

Experts wanted !

FP7-HEALTH-2012-Innovation-1

FP7-HEALTH-2012-Innovation-2

Proposal scoring:

- Each criterion is scored 0-5
- half-scores allowed
- Scores must pass *thresholds* if a proposal is to be considered for funding
- Thresholds apply to individual criteria...

	stage 1			stage2			
	S&T	Impact	total	S&T	Implementation	Impact	total
Innovation -1	4/5	3/5	8/10	4/5	3/5	3/5	12/15
Innovation -2	4/5	4/5	8/10	4/5	3/5	4/5	12/15

Key messages for potentials applicants

Opportunity & Flexibility

Opportunity:

- for ambitious, well-funded R&D projects
- for genuine collaborations (esp. academia – industry), across borders

Flexibility at submission stage:

- Broader topics: more “bottom-up”
 - The size of consortium (beyond min. 3)*
 - The EU contribution requested**
 - The duration of the project***
- } is for applicants to decide

(with the exception of 3-5 max. for the "SMEs for innovation" call,
** within ceiling, ***some exceptions)*

- Analyse the work programme carefully
 - Apply if you see a clear opportunity that fits your strategy
 - Chose your partners carefully
 - Do not view EC grants only as a source of cash, but as a means to access know-how & resources from partners.
 - Managing the project yourself is a major task – it needs to be properly planned & resourced – but you have control.
- Use support structures:
National Contact Points (NCPs), Fit-for-Health, ...



Health Research




- Home
- About Health Research
- Newsroom
- Find a call
- Get support
- International cooperation
- SMEs in Health Research
- Events
- Library
- Useful links



Previous Programmes



Health Research homepage



Highlights

- **New: FP7 Health - 2012 orientation paper** [here](#)

The 2012 calls are expected to be published in July 2011.

- The European and Developing Countries Clinical Trials Partnership ([EDCTP](#)) has launched new calls for proposals (deadline: 14 June 2011).
- [Publication on "International Cooperation in EU-funded Health Research"](#)
- **News alert:** www.healthcompetence.eu, a new interactive platform on European health research

[More highlights ...](#)

Health is our priority

The objective of health research under FP7 is to improve the health of European citizens

Latest News

- [Scientists discover three human gut types; what's yours?](#)

In the same way humans can be divided into blood groups, EU-funded scientists have now discovered that we can categorise ourselves by gut type too. [read more](#) [Date: 2011-04-26]

[more news](#)

Events

- **Register now European Perspectives in Personalised Medicine Conference**, 12 - 13 May 2011, Brussels. Find more information [here](#).
- **Register now FP7 Health - Open Information Day & Partnering event**, 9 June 2011, Brussels. Find more information [here](#).

Thank you

Contacts & Information:

FP7 Health web site: <http://cordis.europa.eu/fp7/health>

Support: http://cordis.europa.eu/fp7/health/support_en.html

Registration as an **Expert:** <https://cordis.europa.eu/emmfp7/>

FitForHealth: www.fitforhealth.eu


EC projects database: www.healthcompetence.eu

National Contact Points (NCP):

http://cordis.europa.eu/fp7/health/ncp_en.html

The Health Theme

Three main activities ("pillars")



cross-cutting issues: **international cooperation, SMEs, child health, ageing populations, gender-related health issues**

Activity 4: Support actions & response to policy needs

Orientations for 2012 WP

Activity 1

Biotechnology, generic tools and medical technologies for human health

**YOU MUST REFER TO THE FINAL PUBLISHED CALL FOR PROPOSALS
for confirmation of deadlines, conditions & final topic descriptions.**

1.2 - Detection, diagnosis and monitoring

1.2-1 Development of technologies with a view to patient group stratification for personalised medicine applications.

Funding scheme: CP-FP, SME-topic (min. 30% for SMEs)
max. €6m/project. >10 projects to be funded

1.4 - Innovative therapeutic approaches & interventions

1.4-1 Innovative approaches to solid organ transplantation.

Funding scheme: CP-FP, SME-topic (min. 15% for SMEs)
max. €6m/project, ~3 projects to be funded

1.4-2 Medical technology for transplantation and bioartificial organs. [“SMEs for Innovation” call]

Funding scheme: CP-FP, SME-topic (min. 50% for SMEs)
3-5 partners, max. €6m/project. 5-7 projects to be funded

1.4 - Innovative therapeutic approaches & interventions

1.4-3 Innovative strategies for translation of stem cell based therapies in regenerative medicine (EU-Australia cooperation)

Funding scheme: CP-FP, SME-topic (min. 15% for SMEs)
max €6m/project, max 1 project to be funded

1.4-4 Targeted nucleic acid delivery as an innovative therapeutic or prophylactic approach.

Funding scheme: CP-FP, Industry-topic (min. 30% for industry, including SMEs); max €6m/project, ~3 projects to be funded

Orientations for 2012 WP

Activity 2 Translating research for human health

2.1.1 – Large-scale data gathering

2.1.1.1-A Support for international rare diseases research.

Funding scheme: SA, max. €2m/project, max. 1 project

2.1.1.1-B Clinical utility of -omics for better diagnosis of rare diseases.

Funding scheme: CP-IP, SME-topic (min. 30% for SMEs); max. €12m/project, max. 2 projects

2.1.1.1-C Databases, biobanks rare diseases research.

Funding scheme: CP-IP, max. €12m/project, max. 1 project

2.1.1 – Large-scale data gathering

2.1.1-2 Validation of -omics based biomarkers for diseases affecting the elderly.

Funding scheme: CP-IP, SME-topic (min. 30% for SMEs)
max. €12m/project, up to ~2-3 projects

2.1.1-3 Statistical methods for collection and analysis of -omics data.

Funding scheme: CP-FP, SME-topic (min. 15% for SMEs)
max. €6m/project, ~1 project to be funded

2.1.2 – Systems Biology

2.1.2-1 Systems medicine: SME-driven research applying systems biology approaches to address medical & clinical needs

Funding scheme: CP-FP, SME-topic (min. 30% for SMEs)
max. €3m/project, up to 6-8 projects

2.1.2-2 Systems medicine: applying systems biology approaches for understanding multifactorial human diseases and their co-morbidities.

Funding scheme: IP, max. €12m/project, up to ~3-4 projects

2.1.2-3 Preparing for the future research and innovation activities in systems medicine.

Funding scheme: CA, max. €3m/project, max. 1 project funded

2.2.2 – Human development and ageing

2.2.2-1 Integrative systems biology and comparative genomics for studying human ageing and/or most common age-related diseases.

Funding scheme: CP-FP, SME-topic (min. 30% for SMEs)
max. €6m/project. Up to ~3 projects

2.2.2-2 Investigator-driven clinical trials for optimisation of management of elderly patients with multiple diseases.

Funding scheme: CP-FP, SME-topic (min. 15% for SMEs)
max. €6m/project. Up to ~3 projects

2.3 – Translational research in major infectious diseases

Covers major HIV/AIDS, malaria, tuberculosis, hepatitis, neglected infectious diseases, emerging epidemics, fungal pathogens, as well as anti-microbial drug resistance.

2.3.0-1 Diagnostics for infectious diseases in humans [“SMEs for Innovation” call]

Funding scheme: CP-FP, SME-topic (min. 50% for SMEs)
3-5 partners, max. €6m/project. Up to ~6 projects

2.3.0-2 ERA-NET on infectious diseases [ERA-NET call]

Funding scheme: CA, max. €2m/project, max. 1 project

2.3.2 – HIV/AIDS, malaria and tuberculosis

2.3.2-1 Co-infection of HIV/AIDS, malaria, tuberculosis and/or hepatitis.

Funding scheme: CP-FP, max. €6m/project, up to 2-3 projects

2.3.2-2 Co-morbidity between infectious diseases and non-communicable diseases.

Funding scheme: CP-FP, max. €6m/project, up to 2-3 projects

2.3.2 – HIV/AIDS, malaria and tuberculosis

2.3.2-3 Prevention and treatment for HIV/AIDS, malaria and tuberculosis.

Small consortia encouraged (3-5 partners), duration 1-3 years.

Funding scheme: CP-FP, SME-topic (min. 15% for SMEs)
max. €6m/project, up to 2-3 projects

2.3.2-4 Low-cost interventions for disease control in resource poor settings.

Funding scheme: CP-FP, max. €3m/project, up to 3-4 projects

Action to support preparation of 2nd phase of EDCTP

Funding scheme: CSA, max. €10m. (named beneficiary)

2.4.3 – Diabetes and obesity

2.4.3-1 Innovative approaches to manage diabetes.

Funding scheme: CP-FP, SME-topic (min. 30% for SMEs)
max. €6m/project. Up to 3-4 projects

2.4.3-2 Investigator-driven clinical trials for type 1 diabetes research.

Funding scheme: CP-FP, max. €6m/project, up to 2-3 projects

2.4.4 – Rare diseases

2.4.4-1 Preclinical and/or clinical development of substances with a clear potential as orphan drugs.

Funding scheme: CP-FP, Industry-topic (min. 30% for industry, including SMEs); max €6m/project, up to ~10 projects

2.4.4-2 Observational trials in rare diseases.

Funding scheme: CP-FP, max. €3m/project, ~3-4 projects

2.4.4-3 Best practice and knowledge sharing in the clinical management of rare diseases.

Funding scheme: CA, max. €2m/project, max. 1 project

2.4.5 – Chronic diseases

2.4.5-1 Technological approaches to combating sensory impairments. [“SMEs for Innovation” call]

Funding scheme: CP-FP, SME-topic (min. 50% for SMEs)
3-5 partners, max. €6m/project. Up to ~5-6 projects

2.4.5-2 Biomarkers and diagnostics for chronic inflammatory diseases of the joints and/or digestive system.

Funding scheme: CP-FP, SME-topic (min. 15% for SME)
max. €6m/project. Up to ~2 projects

Orientations for 2012 WP

Activity 3 Optimising the delivery of healthcare

3.2 – Quality, efficiency and solidarity of healthcare systems

3.2-1 Improving the organisation of health service delivery.

Funding scheme: CP-FP, max. €3m/project, up to ~7-8 projects

3.2-2 New methodologies for health technology assessment

Funding scheme: CP-FP, max. €3m/project, up to ~2-3 projects

3.2-3 Social innovation for active and healthy ageing

Funding scheme: CP-FP, max. €3m/project, up to ~1-2 projects

3.4 – International public health & health systems

3.4-1 Research on Health systems and services in low/middle income countries.

- Projects should generally be 5 years in duration.
- **Min. 6 different ICPC partners & 2 EU/AC partners from different countries.**

Funding scheme: CP-FP (SICA), max. €6m/project, ~3 projects

Orientations for 2012 WP

Activity 4 Other actions across the theme

Actions across the Health theme

4.1 – CSAs across the theme

4.1-1 Network to encourage knowledge transfer activity in FP-funded health research (especially in academic and governmental organisations).

Funding scheme: CA, max. €2m/project, up to 1 project.

4.1-2 Training actions linked to intellectual property rights management and knowledge transfer.

Funding scheme: CA, max. €2m/project, up to 1 project

4.1-3 Support for presidency events. Organisation of supporting actions and events related to the EU Presidency.

Funding scheme: SA, max. €0.1m/project, up to 2-3 projects

Actions across the Health theme

4.1 – CSAs across the theme

4.1-4 Communicating the benefits of European research to the general public.

Funding scheme: CA, max. €1m/project, up to 1-2 projects

4.1-5 Preparing the future for health research & innovation

Funding scheme: SA, max. €0.5m/project, up to 1-2 projects

4.1-6 Setting health-related development goals beyond 2015

Funding scheme: CA, max. €2m/project, up to 1 project